# Inipharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inipharm

- Industry: Biotechnology
- Headquarters: Bellevue, US
- Website: www.inipharm.com
- Total disclosed funding: $35M
- Latest round: Series A (Nov 11, 2020)
- Investors on record: 4

## About

Inipharm, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies for severe liver diseases, particularly targeting HSD17B13 to improve liver health.Founded in 2018 and headquartered in Bellevue, US, Inipharm, Inc. operates as a stand-alone entity without any subsidiaries. The company was established with a focus on addressing unmet medical needs in liver disease treatment. The latest funding round, Series A, raised USD 35.00 mn on November 11, 2020, co-led by 5AM Ventures and Wu Capital, with participation from Frazier Healthcare Partners and Jubilant Biosys.Inipharm is a clinical-stage biopharmaceutical company specializing in the development of small-molecule therapies targeting severe liver diseases. Its lead product, INI-822, is currently undergoing Phase 1 clinical trials for metabolic dysfunction-associated steatotic liver disease (MASH). This first-in-class small molecule inhibitor aims to mitigate the progression of fibrotic liver diseases by altering lipid metabolism and improving liver enzyme levels. Inipharm's products are designed for healthcare providers, hospitals, and research institutions in key markets such as the United States, Europe, and Asia, specifically targeting hepatology professionals.Inipharm's revenue model focuses on partnerships and collaborations in the biopharmaceutical sector. The company engages in B2B transactions, collaborating with research institutions and clinical trial organizations. Partnerships may include licensing agreements with larger pharmaceutical firms, utilizing their distribution and commercialization capabilities. Financial arrangements typically involve milestone payments based on clinical development progress and potential royalties from future product sales. The lead product, INI-822, presents significant revenue potential as successful clinical outcomes may result in lucrative agreements with pharmaceutical partners for market introduction.Inipharm plans to leverage its recent Series A funding of USD 35.00 mn to support the advancement of its lead product, INI-822, through ongoing clinical trials and the exploration of strategic partnerships for further development. The company is targeting expansion into additional markets in Europe and Asia by 2023, aiming to enhance its reach within the hepatology field. Additionally, Inipharm is focused on introducing new therapeutics that address other liver-related conditions, reinforcing its commitment to addressing critical healthcare needs.

## Funding rounds

- Series A, Nov 11, 2020, $35M — Frazier Healthcare Partners, 5AM Ventures, Wu Capital, Jubilant Biosys

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A
- Wu Capital — Series A
- Jubilant Biosys — Series A